Description

CJC-1295 Without DAC 5mg – Modified GRF 1-29 Research Peptide

CJC-1295 Without DAC 5mg is a synthetic 29-amino-acid research peptide associated with scientific investigations into growth hormone-releasing hormone (GHRH) receptor signalling, pituitary endocrine regulation and peptide structure-activity relationships. Also known as Modified GRF (1-29) or Mod GRF 1-29, this compound is a modified analogue of the biologically active N-terminal region of human growth hormone-releasing hormone.

The peptide contains four amino acid substitutions relative to native GHRH(1-29). These modifications have made it a subject of interest in peptide engineering and endocrine research, particularly when investigating how molecular structure influences receptor interactions and resistance to peptide degradation.

Unlike CJC-1295 with DAC, the without-DAC form does not contain the additional albumin-binding drug affinity complex. Consequently, research findings involving the long-acting DAC-modified compound cannot automatically be applied to Modified GRF 1-29.

The 5mg designation refers to the labelled quantity of research material. It does not represent a recommended human dose or independently verify the identity, purity or biological activity of the supplied peptide.

What Is CJC-1295 Without DAC 5mg?

CJC-1295 without DAC is a commercial name commonly used for Modified Growth Hormone-Releasing Factor (1-29).

Modified GRF 1-29 is a 29-residue synthetic analogue of growth hormone-releasing hormone, a naturally occurring hypothalamic peptide involved in the regulation of growth hormone secretion.

The reference peptide differs from native GHRH(1-29) at four positions: 2, 8, 15 and 27.

These substitutions are relevant to molecular identity, peptide stability and experimental receptor activity.

The compound belongs to the GHRH analogue family rather than the ghrelin receptor agonist family that includes peptides such as GHRP-2, GHRP-6 and ipamorelin.

CJC-1295 Without DAC 5mg Product Specifications

• Product Name: CJC-1295 Without DAC 5mg
• Alternative Names: Modified GRF (1-29), Mod GRF 1-29, CJC-1295 No DAC
• Peptide Classification: Synthetic GHRH analogue
• Reference Peptide Length: 29 amino acid residues
• Reference Molecular Formula: C152H252N44O42
• Approximate Molecular Weight: 3,367.9 g/mol (free peptide)
• Reference Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
• Structural Substitutions: D-Ala2, Gln8, Ala15 and Leu27
• C-Terminal Structure: Amidated
• DAC Modification: Absent
• Labelled Quantity: 5mg
• Research Target: Growth hormone-releasing hormone receptor (GHRHR)
• Research Category: Endocrinology and peptide receptor research
• Research Focus: GHRH receptor signalling, pituitary biology and peptide stability
• Purity: Requires batch-specific verification
• Salt Form: Confirm with manufacturer
• Physical Form: Confirm with manufacturer
• Storage: Follow verified manufacturer instructions
• Intended Use: Laboratory research

The reference molecular formula and molecular weight describe the unconjugated peptide. Commercial preparations may contain counterions, water or other formulation components that influence analytical measurements.

Understanding the Modified GRF 1-29 Molecular Structure

Modified GRF 1-29 contains 29 amino acid residues connected through peptide bonds.

Its molecular design is based on the first 29 residues of human growth hormone-releasing hormone.

The four principal substitutions are:

• Position 2 – D-Alanine: Replaces the L-alanine residue found in the native fragment.
• Position 8 – Glutamine: Replaces asparagine.
• Position 15 – Alanine: Replaces glycine.
• Position 27 – Leucine: Replaces methionine.

These modifications distinguish the reference molecule from sermorelin, which corresponds to the unmodified GHRH(1-29) fragment.

The peptide also has a C-terminal amide group, an important structural feature that should be confirmed during identity testing.

How Does CJC-1295 Without DAC Work?

Modified GRF 1-29 is designed around the receptor-associated activity of growth hormone-releasing hormone.

The GHRH receptor is a G-protein-coupled receptor expressed by somatotroph cells in the anterior pituitary gland.

Natural GHRH receptor activation is associated with intracellular cyclic AMP signalling and regulation of growth hormone secretion.

Modified GRF 1-29 is investigated in relation to this signalling pathway because its molecular structure is derived from the active region of GHRH.

However, direct controlled human evidence establishing the pharmacokinetic properties, long-term safety or clinical effectiveness of this particular without-DAC peptide remains insufficient.

Scientific Research Into CJC-1295 Without DAC 5mg

1. Growth Hormone-Releasing Hormone Research

Growth hormone-releasing hormone is produced by specialised neurons in the hypothalamus.

It participates in the regulation of growth hormone secretion by interacting with receptors on pituitary somatotroph cells.

Research involving GHRH and synthetic analogues has helped scientists investigate how peptide hormones communicate with endocrine tissues.

Modified GRF 1-29 is relevant to this research because its structure is based on the active N-terminal region of GHRH.

Findings involving native GHRH, sermorelin or DAC-modified CJC-1295 should not be presented as direct clinical evidence for the without-DAC product.

2. GHRH Receptor Signalling

The growth hormone-releasing hormone receptor is involved in the regulation of pituitary growth hormone secretion.

Receptor activation stimulates intracellular pathways involving cyclic AMP and protein kinase A.

These signals influence the activity of growth hormone-producing cells.

Modified GRF 1-29 provides a structurally relevant compound for investigating GHRH receptor pharmacology.

Its exact receptor activity must be established under defined experimental conditions rather than inferred from its commercial name alone.

3. Peptide Stability and Structural Modification

Peptides can undergo degradation through enzymatic activity and chemical reactions.

Modifications to amino acid sequences are commonly investigated as a way to alter peptide stability and biological behaviour.

Modified GRF 1-29 contains four substitutions that distinguish it from native GHRH(1-29).

These substitutions are relevant to research into peptide structure-activity relationships.

However, the presence of stabilising substitutions does not establish a specific human elimination half-life.

4. Pituitary Endocrine Regulation

The anterior pituitary gland produces hormones involved in growth, metabolism, reproduction and stress responses.

Growth hormone secretion is regulated by a combination of stimulatory and inhibitory signals.

GHRH stimulates the growth hormone pathway, while somatostatin contributes to inhibitory regulation.

Research involving GHRH analogues can help scientists investigate how these systems interact.

Modified GRF 1-29 is relevant to this field because of its structural relationship to endogenous GHRH.

5. Growth Hormone and IGF-1 Research

Growth hormone participates in the regulation of insulin-like growth factor 1, commonly abbreviated IGF-1.

IGF-1 is involved in multiple physiological processes, including growth-related cellular signalling.

Published human studies of CJC-1295 with DAC reported changes in growth hormone and IGF-1 concentrations.

However, those findings involved the albumin-binding form of the molecule.

They do not establish equivalent responses or exposure durations for CJC-1295 without DAC.

6. Structure-Activity Relationship Research

Structure-activity relationship research examines how chemical modifications influence biological properties.

Modified GRF 1-29 is an example of a synthetic peptide containing targeted amino acid substitutions.

Researchers may investigate how these substitutions affect molecular stability, receptor interactions and other experimental characteristics.

Such studies require accurately characterised peptide material and suitable controls.

Analytical confirmation is especially important because the names CJC-1295, Modified GRF 1-29 and CJC-1295 No DAC are used inconsistently in some commercial sources.

7. Growth Hormone Secretagogue Pathway Research

Growth hormone secretion can be influenced by several receptor systems.

GHRH analogues interact with the GHRH-associated signalling pathway.

Other synthetic peptides, including GHRP-2 and GHRP-6, are associated with the growth hormone secretagogue receptor GHSR-1a.

These receptor pathways differ in their molecular mechanisms.

Research involving one receptor family cannot automatically establish the pharmacology of compounds acting through another.

8. Albumin Binding and Peptide Pharmacokinetics

Albumin is a major circulating protein involved in transporting various endogenous and externally introduced molecules.

The original CJC-1295 DAC construct contains an additional chemical modification designed to interact with albumin.

This modification is associated with prolonged systemic exposure in published human studies.

Modified GRF 1-29 lacks the albumin-binding DAC group.

Consequently, the pharmacokinetic results obtained with CJC-1295 DAC should not be transferred to the without-DAC form.

CJC-1295 Without DAC 5mg vs 2mg

CJC-1295 Without DAC 5mg and CJC-1295 Without DAC 2mg are intended to represent the same reference peptide at different labelled quantities.

• 5mg Product: Labelled as containing 5mg of research material.
• 2mg Product: Labelled as containing 2mg of research material.
• Molecular Structure: Both should correspond to the same 29-residue Modified GRF 1-29 sequence.
• Research Category: Both belong to the GHRH analogue research category.
• Purity and Identity: Must be verified separately for each product batch.

The difference in labelled quantity does not establish a difference in molecular potency, purity or suitability for a particular experiment.

CJC-1295 With DAC vs Without DAC

CJC-1295 with DAC and without DAC are chemically distinct research compounds.

• Without DAC: A 29-residue peptide commonly called Modified GRF 1-29.
• With DAC: Contains an additional albumin-binding chemical group.
• Reference Molecular Weight Without DAC: Approximately 3,367.9 g/mol.
• Reference Molecular Weight With DAC: Approximately 3,647.2 g/mol.
• Albumin Binding: The DAC form is designed for albumin binding; the without-DAC form lacks that modification.
• Clinical Evidence: Published human pharmacokinetic studies concern the DAC-modified compound.

The long half-life reported for CJC-1295 DAC is not an established pharmacokinetic property of Modified GRF 1-29.

Modified GRF 1-29 vs Sermorelin

Sermorelin is based on the first 29 amino acid residues of naturally occurring growth hormone-releasing hormone.

Modified GRF 1-29 contains four substitutions relative to the corresponding native fragment.

These modifications distinguish the molecules chemically.

Although both are associated with GHRH receptor research, they should not be treated as interchangeable without direct supporting evidence.

Modified GRF 1-29 vs Ipamorelin

Modified GRF 1-29 and ipamorelin are different synthetic peptides associated with growth hormone-related research.

Modified GRF 1-29 is a 29-residue GHRH analogue.

Ipamorelin is a synthetic pentapeptide associated with ghrelin receptor signalling.

The two peptides differ in molecular structure, receptor targets and experimental evidence.

Research findings involving ipamorelin cannot establish the safety or effectiveness of Modified GRF 1-29.

CJC-1295 Without DAC and Muscle Growth Research

CJC-1295 without DAC is sometimes discussed in connection with muscle development because of its association with growth hormone signalling.

However, activation of a hormonal pathway does not demonstrate sustained increases in skeletal muscle mass or physical strength.

There is insufficient reliable clinical evidence establishing that Modified GRF 1-29 improves muscle growth, exercise recovery or athletic performance in humans.

Such outcomes should not be advertised as proven product benefits.

CJC-1295 Without DAC and Weight Management

CJC-1295 without DAC is not an established weight-loss treatment.

Its principal research association involves GHRH receptor signalling and pituitary endocrinology.

There is insufficient clinical evidence demonstrating sustained fat loss, appetite suppression or obesity treatment with Modified GRF 1-29.

Claims of guaranteed fat burning or metabolic improvement are therefore unsupported.

Understanding the CJC-1295 Without DAC 5mg Label

The 5mg designation refers to the labelled quantity of peptide material.

It does not represent a recommended human dose or independently verify the actual amount of active peptide present.

Researchers should confirm whether the stated mass refers to the peptide itself or includes counterions and other formulation components.

Batch-specific documentation is necessary to verify the product’s identity and analytical specifications.

CJC-1295 Without DAC 5mg Research Quality

Important considerations when evaluating Modified GRF 1-29 research material include:

• Confirmation of the complete 29-amino-acid sequence
• Verification of D-alanine at position 2
• Confirmation of substitutions at positions 8, 15 and 27
• Verification of C-terminal amidation
• Confirmation that the DAC modification is absent
• Identification of the supplied salt form
• Batch-specific certificate of analysis
• Appropriate analytical purity testing
• Mass spectrometry or another suitable identity test
• Accurate labelled peptide quantity
• Manufacturer and batch traceability
• Documentation of counterions and formulation components
• Verified packaging specifications
• Product-specific storage and stability documentation
• Clearly stated research-use classification

Storage and Handling of CJC-1295 Without DAC

Modified GRF 1-29 research material should be stored according to verified manufacturer instructions.

Storage requirements depend on the peptide’s physical form, salt form, formulation and packaging.

Researchers should not assume that all CJC-1295 without DAC products have identical stability or shelf-life characteristics.

Laboratory handling should follow relevant safety documentation and institutional procedures.

Safety and Scientific Limitations

CJC-1295 without DAC is an investigational peptide without an established human clinical safety profile.

Potential concerns include endocrine disturbances, changes in growth hormone and IGF-1 signalling, peptide-related impurities and unknown long-term consequences.

Human pharmacokinetic studies involving CJC-1295 with DAC do not establish the safety of the without-DAC form.

Research-grade Modified GRF 1-29 must not be assumed suitable for human administration.

The peptide is not an established approved medicine for weight management, muscle development or other therapeutic applications in the United Kingdom.

This information is intended for scientific and educational purposes only and does not provide medical advice, human dosing recommendations or administration instructions.

Frequently Asked Questions About CJC-1295 Without DAC 5mg

What is CJC-1295 Without DAC 5mg?

It is a product listing for Modified GRF 1-29, a synthetic GHRH analogue with a labelled quantity of 5mg.

What does Modified GRF 1-29 mean?

It refers to a modified 29-amino-acid fragment of growth hormone-releasing factor.

Is CJC-1295 No DAC the same as Modified GRF 1-29?

The names are commonly used interchangeably in commercial listings, but the exact molecular identity must be verified.

How many amino acids are in Modified GRF 1-29?

The reference peptide contains 29 amino acid residues.

What is the molecular weight of CJC-1295 without DAC?

The reference unconjugated peptide has an approximate molecular weight of 3,367.9 g/mol.

What does without DAC mean?

It means the peptide lacks the albumin-binding drug affinity complex found in CJC-1295 DAC.

What is the difference between the 5mg and 2mg versions?

The main labelled difference is the quantity of research material. Both should have the same reference molecular structure.

Is CJC-1295 without DAC the same as sermorelin?

No. Modified GRF 1-29 contains four amino acid substitutions relative to sermorelin.

Is CJC-1295 without DAC a weight-loss peptide?

No. It is not an established treatment for obesity or weight management.

Does CJC-1295 without DAC increase muscle mass?

There is insufficient reliable clinical evidence demonstrating sustained muscle growth in humans.

Is CJC-1295 without DAC approved for medical use?

It is not an established approved treatment for weight loss, muscle growth or other medical conditions in the United Kingdom.

What does the 5mg designation mean?

It refers to the labelled quantity of peptide material, not a recommended human dose.

CJC-1295 Without DAC 5mg – Product Summary

CJC-1295 Without DAC 5mg, commonly known as Modified GRF 1-29, is a synthetic 29-amino-acid peptide associated with GHRH receptor and endocrine signalling research.

Its four amino acid substitutions distinguish it from native GHRH(1-29), while the absence of the DAC modification distinguishes it from the long-acting CJC-1295 construct.

Although the peptide is relevant to biochemical and endocrinology research, direct human clinical evidence establishing its safety or therapeutic effectiveness remains insufficient.

Researchers should verify the exact molecular identity, purity, salt form, labelled quantity and batch-specific documentation before selecting CJC-1295 Without DAC 5mg for laboratory investigation.